Creo Medical Group PLC - Asset Resilience Ratio
Creo Medical Group PLC (CREO) has an Asset Resilience Ratio of -0.29% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CREO working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Creo Medical Group PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Creo Medical Group PLC.
Liquid Assets Composition Over Time
This chart breaks down Creo Medical Group PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Creo Medical Group PLC's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX-200.00K | -0.29% |
| Total Liquid Assets | GBX-200.00K | -0.29% |
Asset Resilience Insights
- Limited Liquidity: Creo Medical Group PLC maintains only -0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Creo Medical Group PLC Industry Peers by Asset Resilience Ratio
Compare Creo Medical Group PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Eurobio Scientific SA
PA:ALERS |
Medical Devices | 10.52% |
|
Profound Medical Corp
TO:PRN |
Medical Devices | 67.66% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
|
Epitomee Medical Ltd
TA:EPIT |
Medical Devices | 0.24% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
Annual Asset Resilience Ratio for Creo Medical Group PLC (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Creo Medical Group PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 20.23% | GBX15.50 Million ≈ $1.89K |
GBX76.60 Million ≈ $9.32K |
+20.44pp |
| 2022-12-31 | -0.20% | GBX-153.00K ≈ $-18.62 |
GBX75.34 Million ≈ $9.17K |
-0.08pp |
| 2020-12-31 | -0.12% | GBX-112.00K ≈ $-13.63 |
GBX92.46 Million ≈ $11.25K |
-- |
About Creo Medical Group PLC
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices del… Read more